{
    "project_id": "171323",
    "broad_study_type": "other",
    "narrow_study_type": "pharmacogenomics",
    "trial_phase": "N/A",
    "observational_timeframe": "N/A",
    "justification": "This proposal aims to pursue and further expand our previous findings concerning the relationship between genetic variations in a UGT gene and response to an anticancer drug.",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "We believe that the study of classical single nucleotide polymorphisms (SNPs) to epigenomic and new splicing events is critical for a better understanding underlying interindividual variations in xeno- and endobiotic glucuronidation by human UGT enzymes and to fully appreciate their in vivo significance, particularly in drug response.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "unclear",
    "gender_focus": "mixed",
    "vulnerable_populations": "no",
    "rare_disease": "no",
    "population_description": "patients treated with an anticancer drug",
    "intervention_category": "drug",
    "intervention_name": "anticancer drug",
    "control_type": "no_control",
    "dose_response": "unclear",
    "combination_therapy": "no",
    "personalized_medicine": "yes",
    "primary_outcome": "drug response",
    "primary_outcome_type": "biomarker",
    "safety_focus": "no",
    "quality_of_life": "no",
    "biomarker_endpoints": "yes",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "no",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "yes",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "no",
    "ethics_focus": "yes",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "cancer",
    "disease_stage": "unclear",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "yes",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "long_term",
    "multicenter": "no",
    "healthcare_setting": "laboratory",
    "disease_area": "cancer",
    "methodology_innovation": "investigating the pharmacogenomics of human UGT enzymes, including the impact of genetic variations, epigenomics, and mRNA splicing on anticancer drug response",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 